Caribou Biosciences Files 8-K Report

TL;DR

Caribou Biosciences filed an 8-K, mostly standard financial updates. No major news.

AI Summary

On April 4, 2024, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no specific material events or financial figures detailed in the provided text.

Why It Matters

This filing indicates Caribou Biosciences is providing updated financial statements and disclosing other events, which is standard practice for public companies to maintain transparency with investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report with no disclosed material events or significant financial changes, indicating low immediate risk.

Key Players & Entities

• Caribou Biosciences, Inc. (company) — Registrant
• 0001619856-24-000018 (filing_id) — Accession Number
• April 04, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global

Filing Documents

• crbu-20240404.htm (8-K) — 34KB
• crbu-20240404xexx991.htm (EX-99.1) — 29KB
• caribou_indlupusxconfere.htm (EX-99.2) — 23KB
• caribou_indlupusxconfere001.jpg (GRAPHIC) — 125KB
• caribou_indlupusxconfere002.jpg (GRAPHIC) — 274KB
• caribou_indlupusxconfere003.jpg (GRAPHIC) — 106KB
• caribou_indlupusxconfere004.jpg (GRAPHIC) — 76KB
• caribou_indlupusxconfere005.jpg (GRAPHIC) — 110KB
• caribou_indlupusxconfere006.jpg (GRAPHIC) — 63KB
• caribou_indlupusxconfere007.jpg (GRAPHIC) — 130KB
• caribou_indlupusxconfere008.jpg (GRAPHIC) — 131KB
• caribou_indlupusxconfere009.jpg (GRAPHIC) — 107KB
• caribou_indlupusxconfere010.jpg (GRAPHIC) — 111KB
• caribou_indlupusxconfere011.jpg (GRAPHIC) — 120KB
• caribou_indlupusxconfere012.jpg (GRAPHIC) — 115KB
• caribou_indlupusxconfere013.jpg (GRAPHIC) — 96KB
• caribou_indlupusxconfere014.jpg (GRAPHIC) — 111KB
• caribou_indlupusxconfere015.jpg (GRAPHIC) — 113KB
• caribou_indlupusxconfere016.jpg (GRAPHIC) — 109KB
• caribou_indlupusxconfere017.jpg (GRAPHIC) — 116KB
• caribou_indlupusxconfere018.jpg (GRAPHIC) — 114KB
• caribou_indlupusxconfere019.jpg (GRAPHIC) — 134KB
• img25401123_0.jpg (GRAPHIC) — 51KB
• 0001619856-24-000018.txt ( ) — 3423KB
• crbu-20240404.xsd (EX-101.SCH) — 2KB
• crbu-20240404_lab.xml (EX-101.LAB) — 23KB
• crbu-20240404_pre.xml (EX-101.PRE) — 13KB
• crbu-20240404_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 4, 2024, Caribou Biosciences, Inc. (the "Company") issued a press release announcing that it has received clearance of its investigational new drug ("IND") application from the U.S. Food and Drug Administration ("FDA") for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, for the treatment of lupus nephritis ("LN") and extrarenal lupus ("ERL"). The phase 1, multicenter, open label, GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. This represents an expansion of CB-010's clinical development to include autoimmune diseases in addition to oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and also is incorporated by reference into this Item 7.01. The Company will host a conference call and webcast today, Thursday, April 4, 2024, at 5:00 pm ET, to discuss the expansion of the clinical development of CB-010 to include autoimmune diseases and the GALLOP Phase 1 clinical trial plans. A copy of the slide presentation to be used during the Company's conference call and webcast is attached hereto as Exhibit 99.2 and incorporated by reference herein. Details for accessing the conference call and webcast are included in Exhibit 99.1. The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing or other document under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), regardless of any general incorporation language in any such filing or document, except as shall be expressly set forth by specific reference in any such filing or document.

01 Other Events

Item 8.01 Other Events. On April 4, 2024, the Company announced that it has received clearance of its IND application from the FDA for for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, for the treatment of LN and ERL. The phase 1, multicenter, open label, GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. This represents an expansion of CB-010's clinical development to include autoimmune diseases in addition to oncology. Patients in both the GALLOP and ANTLER phase 1 clinical trials will be screened for donor-specific antibodies and administered CB-010 manufactured from a donor with partial human leukocyte antigen matching. Cautionary Note Regarding Forward-Looking Statements This Current Report, including Exhibits 99.1 and 99.2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts are forward-looking statements. Forward-looking statements may relate to future events or future performance. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company, its industry, its beliefs, and its assumptions. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to the Company's strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs, including its expectations relating to the timing of the initiation of the GALLOP Phase 1 clinical trial for CB-010. These forward-looking statements also

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Caribou Biosciences, Inc. on April 4, 2024 99.2 Caribou Biosciences, Inc. Webcast Slide Presentation dated April 4, 2024 Regarding Expansion of CB-010 Clinical Development to Include Autoimmune Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: April 4, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR